Ir para o conteúdo principal

Seres Therapeutics (NASDAQ: MCRB) — Perfil da empresa, notícias e dados financeiros

Logo de Seres Therapeutics
MCRB Seres Therapeutics
Seres Therapeutics primary media
Perfil da empresa

Seres Therapeutics

Seres Therapeutics (NASDAQ:MCRB) is a biotechnology company focused on transforming the lives of patients by targeting the microbiome to treat disease and improve human health. It is at the forefront of microbiome therapeutics, advancing a novel class of biological drugs. Seres is engaged in developing a portfolio of product candidates designed to restore the natural ecology of the human microbiome for patients affected by serious diseases. Their projects include therapies for conditions such as Clostridioides difficile infection, ulcerative colitis, and others within the gastrointestinal disease area. The company's objective is to lead in microbiome therapeutics by advancing science and exploring new treatment modalities for a range of diseases linked to the dysfunction of the microbiome.

Resumo

Public USParticipação acionária
2010Ano de fundação
233Funcionários
Massachusetts, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Seres Therapeutics

  • SER-109, an oral microbiome therapeutic for reducing recurrent Clostridioides difficile infection (CDI).
  • SER-287, an oral microbiome treatment for active mild-to-moderate ulcerative colitis.
  • SER-401, a microbiome therapeutic for improving outcomes in melanoma patients undergoing immunotherapy.
  • SER-301, an engineered microbiome therapeutic for inflammatory bowel disease.
  • SER-262, the first synthetically derived microbiome therapeutic aimed at preventing CDI recurrence.
  • Collaborative research projects with leading pharmaceutical companies to develop microbiome-based therapies for various indications.

equipe executiva do Seres Therapeutics

  • Richard N. KenderInterim CEO & Executive Chair
  • Matthew R. HennPresident & Chief Scientific Officer
  • Marella ThorellExecutive VP, CFO & Treasurer
  • Thomas J. DesRosierExecutive VP, Chief Legal Officer & Secretary
  • Kelly BradyExecutive VP & COO
  • Chris McChalicherExecutive VP & CTO
  • Dennis M. WallingSenior VP of Clinical Development & Head of Clinical Research
  • Ann KurowskiSenior Vice President of Regulatory Affairs

Principais indicadores financeiros

Resultados divulgados pela Seres Therapeutics, em USD.

Cap. de mercado
18,1 mi
Receita (TTM)
1,9 mi
P/L
—
LPA (diluído, TTM)
-2.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Seres Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
789 mil-94 mi5,7 mi
0-121,3 mi-146,6 mi
126,3 mi-195,1 mi-113,7 mi
7,1 mi-179,9 mi-250,2 mi